CBIO Catalyst Biosciences Inc.

8.93
-0.01  -0%
Previous Close 8.93
Open 8.94
Price To Book 0.82
Market Cap 106588856
Shares 11,942,729
Volume 61,099
Short Ratio
Av. Daily Volume 269,184

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b trial to be initiated 1Q 2019.
CB 2679d/ ISU304
Hemophilia B
Phase 2/3 top-line data due 3Q 2019.
Marzeptacog alfa
Hemophilia

Latest News

  1. New Research: Key Drivers of Growth for Omega Healthcare Investors, Cinedigm, Cardiovascular, Allegiant Travel, Catalyst Biosciences, and ESCO Technologies — Factors of Influence, Major Initiatives and Sustained Production
  2. Catalyst Biosciences Presents Updated Data from Its Phase 2/3 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors at the 12th Annual EAHAD Congress
  3. Catalyst Biosciences Announces Preclinical Proof-of-Concept Data of Gene Therapy Candidate CB 2679d-GT for the Treatment of Hemophilia B
  4. Catalyst Biosciences to Present at the Annual BIO CEO & Investor Conference
  5. Catalyst Biosciences Announces Oral and Poster Presentations at the 12th Annual Congress of the European Association for Haemophilia and Allied Disorders
  6. Is Catalyst Biosciences, Inc.’s (NASDAQ:CBIO) Balance Sheet A Threat To Its Future?
  7. Zacks.com featured expert Kevin Matras highlights: Net Lease, K12, Brookline Bancorp, Catalyst Biosciences and Knoll
  8. These 5 Stocks Make Great Buys on New Analyst Coverage
  9. Catalyst Biosciences Hosts Research & Development Day Focused on Factor VIIa and Factor IX Hemophilia Programs
  10. Catalyst Biosciences to Host a Research & Development Day Focused on Factor VIIa and Factor IX Hemophilia Programs
  11. Catalyst Biosciences Announces Updated Positive Interim Data from Its Phase 2/3 Study of Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors
  12. What Did Catalyst Biosciences Inc’s (NASDAQ:CBIO) CEO Take Home Last Year?
  13. How Does Catalyst Biosciences Inc (NASDAQ:CBIO)’s Prospect Stack Up To Its Healthcare Peers?